Transplantation of cultured autologous melanocytes: Hope or danger?

Cell Transplantation

Volumn 19, Issue 5, 2010, Pages 639-643

  Czajkowski, Rafal ^a   Pokrywczynska, Marta ^a   Placek, Waldemar ^a   Zegarska, Barbara ^a   Tadrowski, Tadeusz ^a   Drewa, Tomasz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Melanocyte culture; Melanoma; Melanomagenesis; RAS RAF MEK ERK pathway; Vitiligo

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; RAF PROTEIN; RAS PROTEIN;

ARTICLE; AUTOTRANSPLANTATION; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; EXON; GENE MUTATION; HUMAN; HUMAN CELL; MELANOCYTE; PRIORITY JOURNAL; RISK ASSESSMENT; SIGNAL TRANSDUCTION; VITILIGO;

CELLS, CULTURED; HUMANS; MELANOCYTES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VITILIGO;

ANIMALIA;

EID: 77954910767     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368910X491798     Document Type: Article

References (22)

1. Arita, Y.; Santiago-Schwarz, F.; Coppock, D. L. Survival mechanisms induced by 12-O-tetradecanoylphorbol-13-acetate in normal human melanocytes include inhibition of apoptosis and increased Bcl-2 expression. Melanoma Res. 10:412-420; 2000.
2. Bauer, J.; Curtin, J. A.; Pinkel, D.; Bastian, B. C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol. 127:179-182; 2007.
3. Bennett, D. C. How to make a melanoma: What do we know of the primary clonal events? Pigment Cell Melanoma Res. 21:27-38; 2009.
4. Czajkowski, R. Comparison of melanocytes transplantation methods for the treatment of vitiligo. Dermatol. Surg. 30:1400-1405; 2004.
5. Czajkowski, R.; Placek, W.; Drewa, G.; Czajkowska, A.; Uchanska, G. FAMMM syndrome: Pathogenesis and management. Dermatol. Surg. 30:291-296; 2004.
6. Deepa, G.; Sudheer, S.; Pushpa, H. Cultured melanocytes: From skin biopsy to transplantation. Cell Transplant. 17: 351-360; 2008.
7. Demunter, A.; Stas, M.; Degreef, H.; De Wolf-Peeters, C.; van den Oord, J. J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 117:1483-1489; 2001.
8. Dong, J.; Phelps, R. G.; Qiao, R.; Yao, S.; Benard, O.; Ronai, Z.; Aaronson, S. A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63:3883-3885; 2003.
9. Eisinger, M.; Marko, O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc. Natl. Acad. Sci. USA 79: 2018-2022; 1982.
10. Herlyn, M.; Rodeck, U.; Mancianti, M.; Cardillo, F. M.; Lang, A.; Ross, A. H.; Jambrosic, J.; Koprowski, H. Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res. 47: 3057-3061; 1987.
11. Krasagakis, K.; Garbe, C.; Kruger-Krasagakes, S.; Orfanos, C. E. 12-O-tetradecanoylphorbol-13-acetate not only modulates proliferation rates, but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro. J. Invest. Dermatol. 100:653-659; 1993.
12. Landi, M. T.; Bauer, J.; Pfeiffer, R. M.; Elder, D. E.; Hulley, B.; Minghetti, P.; Calista, D.; Kanetsky, P. A.; Pinkel, D.; Bastian, B. C. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521-522; 2006.
13. Lerner, A. B.; Halaban, R.; Klaus, S. N.; Moellmann, G. E. Transplantation of human melanocytes. J. Invest. Dermatol. 89:219-224; 1987.
14. Nageatte, I.; Haluska, F. G. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. Mech. Dis. 4:551-579; 2009.
15. Negrier, S.; Fervers, B.; Bailly, C.; Beckendorf, V.; Cupissol, D.; Doré, J. F.; Dorval, T.; Garbay, J. R.; Vilmer, C. Cutaneous melanoma. Br. J. Cancer 84(Suppl. 2):81-85; 2001.
16. Pollock, P. M.; Harper, U. L.; Hansen, K. S.; Yudt, L. M.; Stark, M.; Robbins, C. M.; Moses, T. Y.; Hostetter, G.; Wagner, U.; Kakareka, J.; Salem, G.; Pohida, T.; Heenan, P.; Duray, P.; Kallioniemi, O.; Hayward, N. K.; Trent, J. M.; Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet. 33:19-20; 2003.
17. Reifenberger, J.; Knobbe, C. B.; Sterzinger, A. A.; Blaschke, B.; Schulte, K. W.; Ruzicka, T.; Reifenberger, G. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer 109:377-384; 2004.
18. Shukla, V. K.; Hughes, D. C.; Hughes, L. E.; McCormick, F.; Padua, R. Ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res. 5:121-127; 1989. (Pubitemid 20018406)
19. Stavroulaki, M.; Kardassis, D.; Chatzaki, E.; Sakellaris, G.; Lindschau, C.; Haller, H.; Tosca, A.; Krasagakis, K. Exposure of normal human melanocytes to a tumor promoting phorbol ester reverses growth suppression by transforming growth factor beta. J. Cell. Physiol. 214: 363-370; 2008.
20. Tucker, M. A. Melanoma epidemiology. Hematol. Oncol. Clin. North Am. 23:383-395; 2009.
21. Ugurel, S.; Thirumaran, R. K.; Bloethner, S. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2:e236; 2007.
22. van Dijk, M. C.; Bernsen, M. R.; Ruiter, D. J. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am. J. Surg. Pathol. 29:1145-1151; 2005.